Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNASDAQ:ALVRNASDAQ:CMMBNASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$0.97-6.7%$0.96$0.61▼$22.20$16.56M-0.141.09 million shs572,819 shsALVRAlloVir$3.25-3.8%$7.45$7.96▼$24.15$16.39M0.6316,085 shs55,606 shsCMMBChemomab Therapeutics$1.21-4.0%$1.21$0.78▼$2.55$17.37M0.55208,924 shs112,792 shsONCOOnconetix$0.09+22.1%$0.09$0.05▼$21.40$5.99M3.497.05 million shs583.33 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+1.96%-2.80%+42.23%+2.97%-95.64%ALVRAlloVir-2.87%-37.52%-53.25%-65.33%-80.41%CMMBChemomab Therapeutics+1.61%+3.28%+18.12%-37.31%+54.79%ONCOOnconetix+8.57%+9.51%+21.99%-86.18%-98.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.5932 of 5 stars0.03.00.00.03.10.00.6ALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ACMMBChemomab Therapeutics3.7074 of 5 stars3.55.00.00.03.81.71.3ONCOOnconetix0.583 of 5 stars0.02.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/AALVRAlloVir 0.00N/AN/AN/ACMMBChemomab Therapeutics 3.00Buy$9.00643.80% UpsideONCOOnconetix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCO, CMMB, ALVR, and ALLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/20/2025CMMBChemomab TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A($559.39) per shareN/AALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AONCOOnconetix$1.87M3.20N/AN/A$3.01 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%N/AALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%N/ACMMBChemomab Therapeutics-$24.22M-$0.90N/AN/AN/AN/A-101.70%-76.18%5/15/2025 (Estimated)ONCOOnconetix-$37.41MN/A0.00∞N/A-2,758.89%N/A-48.09%5/19/2025 (Estimated)Latest ONCO, CMMB, ALVR, and ALLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20N/AN/AN/AN/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.752.75ALVRAlloVirN/A86.7886.78CMMBChemomab TherapeuticsN/A4.574.57ONCOOnconetixN/A0.060.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%ALVRAlloVir66.05%CMMBChemomab Therapeutics46.05%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%ALVRAlloVir32.07%CMMBChemomab Therapeutics11.91%ONCOOnconetix11.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1017.08 million4.43 millionNot OptionableALVRAlloVir1105.04 million3.43 millionOptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableONCOOnconetix1264.55 million57.17 millionN/AONCO, CMMB, ALVR, and ALLR HeadlinesRecent News About These CompaniesOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqApril 30, 2025 | globenewswire.comOnconetix faces third delisting threat since 2022 IPOApril 21, 2025 | bizjournals.comOnco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP TechnologyApril 17, 2025 | accessnewswire.comOnco-Innovations Announces Private PlacementApril 16, 2025 | accessnewswire.comOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comFive things you need to know today, and calming irrational fearsApril 9, 2025 | bizjournals.comOnconetix signs non-binding LOI for potential combination with OcuvexApril 9, 2025 | markets.businessinsider.comCincinnati's Onconetix pursuing merger deal with drug development firmApril 8, 2025 | bizjournals.comOnconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.April 8, 2025 | markets.businessinsider.com🌱 Cincinnati's arena debate heats upApril 6, 2025 | msn.comAnother top executive departs Cincinnati public firmApril 6, 2025 | local12.comOnconetix executive chairman resigns in latest leadership exit; interim CFO named new top leaderApril 5, 2025 | bizjournals.comOnconetix Names Interim CFO Karina Fedasz as Interim CEOApril 3, 2025 | marketwatch.comOnco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety ProfileMarch 26, 2025 | accessnewswire.comOnco-Innovations Extends Marketing ProgramMarch 25, 2025 | accessnewswire.comOnconetix claims validation of prostate cancer test Proclarix in Danish cohortMarch 25, 2025 | finance.yahoo.comOnco-Innovations Provides Update on Use of ProceedsMarch 24, 2025 | accessnewswire.comOnconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohortMarch 24, 2025 | globenewswire.comOnconetix, Inc. to Present Proclarix Study Results at 2025 EAU Congress in MadridMarch 21, 2025 | nasdaq.comOnconetix announces new clinical data for Proclarix to be presented at EAUMarch 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCO, CMMB, ALVR, and ALLR Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$0.97 -0.07 (-6.73%) As of 04:00 PM EasternAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.AlloVir NASDAQ:ALVR$3.25 -0.13 (-3.85%) As of 05/13/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Chemomab Therapeutics NASDAQ:CMMB$1.21 -0.05 (-3.97%) As of 04:00 PM EasternChemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Onconetix NASDAQ:ONCO$0.09 +0.02 (+22.11%) As of 04:00 PM EasternOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
